Asenapine is an atypical antipsychotic used to treat psychiatric conditions such as Schizophrenia and Bipolar Disorder, particularly for managing acute manic or mixed episodes. It works by modulating neurotransmitters in the brain, primarily dopamine and serotonin receptors, to help stabilize mood, reduce psychotic symptoms, and improve overall functioning. The drug was developed in the early 2000s as part of efforts to create antipsychotics with fewer side effects compared to older, typical antipsychotics. Servier Laboratories initially discovered and developed asenapine, and after extensive clinical trials demonstrating efficacy and safety, it received approval from the U.S. Food and Drug Administration in 2009. Since then, it has been available in sublingual and transdermal forms, offering patients more flexible administration options and contributing to improved adherence in long-term psychiatric treatment.
